(Q34994521)

5 August 2017

RNAi-based therapeutics targeting survivin and PLK1 for treatment of bladder cancer (English)

1 reference

5 August 2017

1 reference

Shaguna Seth

1

1 reference

5 August 2017

Yoshiyuki Matsui

2

1 reference

5 August 2017

Kathy Fosnaugh

3

1 reference

5 August 2017

Yan Liu

4

1 reference

5 August 2017

Narendra Vaish

5

1 reference

5 August 2017

Roger Adami

6

1 reference

5 August 2017

Pierrot Harvie

7

1 reference

5 August 2017

Rachel Johns

8

1 reference

5 August 2017

Gregory Severson

9

1 reference

5 August 2017

Tod Brown

10

1 reference

5 August 2017

Akihide Takagi

11

1 reference

5 August 2017

Susan Bell

12

1 reference

5 August 2017

Yan Chen

13

1 reference

5 August 2017

Feng Chen

14

1 reference

5 August 2017

Tianying Zhu

15

1 reference

5 August 2017

Renata Fam

16

1 reference

5 August 2017

Iwona Maciagiewicz

17

1 reference

5 August 2017

Erin Kwang

18

1 reference

5 August 2017

Michael McCutcheon

19

1 reference

5 August 2017

Ken Farber

20

1 reference

5 August 2017

Patrick Charmley

21

1 reference

5 August 2017

Michael E Houston

22

1 reference

5 August 2017

Alan So

23

1 reference

5 August 2017

Michael V Templin

24

1 reference

5 August 2017

Barry Polisky

25

1 reference

5 August 2017

1 March 2011

1 reference

5 August 2017

1 reference

5 August 2017

19

1 reference

5 August 2017

928-935

1 reference

5 August 2017

5

1 reference

Improved specificity of gene silencing by siRNAs containing unlocked nucleobase analogs

5 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Utilization of unlocked nucleic acid (UNA) to enhance siRNA performance in vitro and in vivo

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Investigational therapies for non-muscle invasive bladder cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Analysis of acyclic nucleoside modifications in siRNAs finds sensitivity at position 1 that is restored by 5'-terminal phosphorylation both in vitro and in vivo.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

New therapies for non-muscle-invasive bladder cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Intravesical combination treatment with antisense oligonucleotides targeting heat shock protein-27 and HTI-286 as a novel strategy for high-grade bladder cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Intravesical drug delivery into the bladder to treat cancers

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Antisense-mediated inhibition of survivin, hTERT and VEGF in bladder cancer cells in vitro and in vivo.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Intravesical treatments of bladder cancer: review.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Sequence- and target-independent angiogenesis suppression by siRNA via TLR3

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Targeting survivin in cancer therapy

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Cell type-- dependent effects of Polo-like kinase 1 inhibition compared with targeted polo box interference in cancer cell lines

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

RNA recognition via TLR7 and TLR8.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

A validated mouse model for orthotopic bladder cancer using transurethral tumour inoculation and bioluminescence imaging

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Polo-like kinase 1: target and regulator of transcriptional control

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Validation of telomerase and survivin as anticancer therapeutic targets using ribozymes and small-interfering RNAs.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Effect of small interfering RNA targeting survivin gene on biological behaviour of bladder cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Synthetic nucleic acids as potential therapeutic tools for treatment of bladder carcinoma

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Chemosensitization of bladder cancer cells by survivin-directed antisense oligodeoxynucleotides and siRNA.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Antisense oligodeoxynucleotide therapy for bladder cancer: recent advances and future prospects

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Antisense oligonucleotide therapy in the management of bladder cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer.

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Sequence-specific potent induction of IFN-alpha by short interfering RNA in plasmacytoid dendritic cells through TLR7

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Non-viral tumor necrosis factor-alpha gene transfer decreases the incidence of orthotopic bladder tumors

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

siRNA-mediated down-regulation of survivin inhibits bladder cancer cell growth

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Polo-like kinases and the orchestration of cell division

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Systematic in vitro evaluation of survivin directed antisense oligodeoxynucleotides in bladder cancer cells

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Survivin in apoptosis control and cell cycle regulation in cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

The role of antisense oligonucleotides in the treatment of bladder cancer

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Bladder cancer detection with urinary survivin, an inhibitor of apoptosis

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Unlocked nucleic acid (UNA) and UNA derivatives: thermal denaturation studies

8 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

A survivin gene signature predicts aggressive tumor behavior

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Nonviral cytokine gene therapy on an orthotopic bladder cancer model.

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Quantitative recovery of immunoreactive proteins from clinical samples following RNA and DNA isolation

26 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3098637

Urine detection of survivin and diagnosis of bladder cancer

26 October 2018

1 reference

12 December 2020

Effect of intravesical treatment of transitional cell carcinoma with bacillus Calmette-Guerin and mitomycin C on urinary survivin levels and outcome

1 reference

12 December 2020

Synthesis and evaluation of oligodeoxynucleotides containing acyclic nucleosides: Introduction of three novel analogues and a summary

1 reference

12 December 2020

Tumor Content of the Antiapoptosis Molecule Survivin and Recurrence of Bladder Cancer

1 reference

12 December 2020

Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA

1 reference

12 December 2020

Hsp27 knockdown using nucleotide-based therapies inhibit tumor growth and enhance chemotherapy in human bladder cancer cells

1 reference

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.1038/MT.2011.21

1 reference

5 August 2017

1 reference

5 August 2017

1 reference